Demonstrates faster approval of psychedelics for serious mental illness, suggesting improved treatment options.
A new executive order from the White House could jump‐start additional research and new approvals of psychedelic drugs for the treatment of serious mental illness (SMI). Among its provisions, the April 18 order directs federal agencies to expedite reviews of products that have successfully completed Phase 3 trials, so that they can be more rapidly rescheduled from their current Schedule I (no recognized medical use) status.
No takes yet. Share an insight, caveat, or question.
Gary Enos (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: